Drugs / SYS6043
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07424547 | Mar 2026 → Dec 2029 expected | breast cancer, metastatic neoplasm, ovarian cancer, prostate disorder +1 | Conjupro Biotherapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07833735 | Oct 2026 → Oct 2028 expected | cancer | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07241936 | Nov 2025 → Oct 2027 expected | cancer | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07415863 | Dec 2024 → Dec 2027 expected | — | CSPC Megalith Biopharmaceutical Co.,Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07708753 | Jul 2026 → Oct 2029 expected | fallopian tube cancer, primary peritoneal carcinoma, refractory malignant neoplasm | CSPC Megalith Biopharmaceutical Co.,Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-07-02 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - SYS6043 GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE TREATMENT OF PLATINUM-RESISTANT OVARIAN CANCER, PRIMARY PERITONEAL CARCINOMA AND FALLOPIAN TUBE CANCER irasia.com ↗ |
| 2026-06-02 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Results VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL STUDY DATA OF NOVEL B7-H3 ANTIBODY-DRUG CONJUGATE SYS6043 PRESENTED IN AN ORAL SESSION AT THE 2026 ASCO ANNUAL MEETING irasia.com ↗ |
| 2025-01-16 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - SYS6043 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. irasia.com ↗
The board of directors (the ‘‘Board ’’) of CSPC Pharmaceutical Group Limited (the ‘‘Company ’’, together with its subsidiaries, the ‘‘Group ’’) is pleased to announce that the Investigational New Drug (IND) application for SYS6043 (Antibody-Drug Conjugate) ( the ‘‘Product ’’) developed by the Group has been approved by the U.S. Food and Drug Administration (F DA) to conduct clinical trial in the U.S. |
| 2024-12-20 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - SYS6043 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗
SYS6043 (Antibody-Drug Conjugate) (the ‘‘Product ’’) developed by the Group has obtained clinical trial approva l granted by the National Medical Products Administration of the People ’s Republic of China to conduct clinical trials in China. |
All press releases naming this drug 5 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYS6043 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07708753 ↗ |
| Modality | Other / unclassified | “Different ADCs (DP303c/SYS6043/SYS6002/SYS6010)” NCT07241936 ↗ |
| Route | Intravenous | “intravenous infusion” NCT07241936 ↗ |